Literature DB >> 30526042

Activating β-catenin/Pax6 axis negatively regulates osteoclastogenesis by selectively inhibiting phosphorylation of p38/MAPK.

Zhiwei Jie1,2, Shuying Shen1,2, Xiangde Zhao1,2, Wenbin Xu1,2, Xuyang Zhang1,2, Bao Huang1,2, Pan Tang3, An Qin4, Shunwu Fan1,2, Ziang Xie1,2.   

Abstract

Balance of osteoclast formation is regulated by the receptor activator of NF-κB ligand and extracellular negative regulators such as IFN-γ and IFN-β. However, very little is known about the intrinsic negative regulatory factors of osteoclast differentiation. Recently, the paired-box homeodomain transcription factor Pax6 was shown to negatively regulate receptor activator of NF-κB ligand-mediated osteoclast differentiation. However, the mechanism underlying this regulation is still unclear. In this study, we show that a p38 inhibitor (VX-745) up-regulates the expression of Pax6 during osteoclast differentiation. Subsequently, we found that β-catenin could bind to the proximal region of Pax6 promoter to induce its expression, and this action could be impaired by p38-induced ubiquitin-mediated degradation of β-catenin. Our results suggest that Pax6 is regulated by a novel p38/β-catenin pathway. Pax6 can further regulate the nuclear translocation of NF of activated T cells, cytoplasmic 1. Our study indicates that this novel p38/β-catenin/Pax6 axis contributes to negative regulation of osteoclastogenesis. In addition, our study proposes a novel approach to treat osteoclast-related diseases through the use of VX-745 complemented with the β-catenin activator SKL2001.-Jie, Z., Shen, S., Zhao, X., Xu, W., Zhang, X., Huang, B., Tang, P., Qin, A., Fan, S., Xie, Z. Activating β-catenin/Pax6 axis negatively regulates osteoclastogenesis by selectively inhibiting phosphorylation of p38/MAPK.

Entities:  

Keywords:  SKL2001; VX-745; bone loss; osteoclast; therapeutic

Mesh:

Substances:

Year:  2018        PMID: 30526042     DOI: 10.1096/fj.201801977R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  7 in total

1.  TNFRSF9 Suppressed the Progression of Breast Cancer via the p38MAPK/PAX6 Signaling Pathway.

Authors:  Xiaorong Liu; Yehui Zhou; Chenglin Qin; Xun Zhu
Journal:  J Oncol       Date:  2022-06-28       Impact factor: 4.501

2.  Sophoridine exerts tumor-suppressive activities via promoting ESRRG-mediated β-catenin degradation in gastric cancer.

Authors:  Zhiyang Peng; Qing Guan; Jianfei Luo; Wenhong Deng; Jiasheng Liu; Ruicheng Yan; Weixing Wang
Journal:  BMC Cancer       Date:  2020-06-22       Impact factor: 4.430

3.  Panax notoginseng saponins attenuate intervertebral disc degeneration by reducing the end plate porosity in lumbar spinal instability mice.

Authors:  Hao Hu; Yan Chen; Fangli Huang; Bolin Chen; Zhiyuan Zou; Bizhi Tan; Hualin Yi; Chun Liu; Yong Wan; Zemin Ling; Xuenong Zou
Journal:  JOR Spine       Date:  2021-11-30

4.  Mechanical force promotes dimethylarginine dimethylaminohydrolase 1-mediated hydrolysis of the metabolite asymmetric dimethylarginine to enhance bone formation.

Authors:  Ziang Xie; Lei Hou; Shuying Shen; Yizheng Wu; Jian Wang; Zhiwei Jie; Xiangde Zhao; Xiang Li; Xuyang Zhang; Junxin Chen; Wenbin Xu; Lei Ning; Qingliang Ma; Shiyu Wang; Haoming Wang; Putao Yuan; Xiangqian Fang; An Qin; Shunwu Fan
Journal:  Nat Commun       Date:  2022-01-10       Impact factor: 17.694

5.  A Novel Inhibitor INF 39 Promotes Osteogenesis via Blocking the NLRP3/IL-1β Axis.

Authors:  Wenxiang Chen; Pan Tang; Shunwu Fan; Xuesheng Jiang
Journal:  Biomed Res Int       Date:  2022-07-13       Impact factor: 3.246

6.  Selumetinib - a potential small molecule inhibitor for osteoarthritis treatment.

Authors:  Xiaohang Zheng; Jianxin Qiu; Wenjun Pan; Yuhang Gong; Weikang Zhang; Ting Jiang; Lihua Chen; Weifu Chen; Zhenghua Hong
Journal:  Front Pharmacol       Date:  2022-09-27       Impact factor: 5.988

7.  Loss of GSTO2 contributes to cell growth and mitochondria function via the p38 signaling in lung squamous cell carcinoma.

Authors:  Ryusuke Sumiya; Masayoshi Terayama; Teruki Hagiwara; Kazuaki Nakata; Keigo Sekihara; Satoshi Nagasaka; Hideki Miyazaki; Toru Igari; Kazuhiko Yamada; Yuki I Kawamura
Journal:  Cancer Sci       Date:  2021-11-21       Impact factor: 6.716

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.